By Dean Seal Mesoblast said regulators have granted their rare pediatric disease designation to its cell therapy Revascor for children with hypoplastic left.
By Chris Wack Processa Pharmaceuticals shares were up 60% to 32 cents in premarket trading after the company said it plans to expand the development of Next.
Insurance giants like Humana, UnitedHealth, and CVS Health have made big bets on Medicare Advantage. But the program’s rising utilization rates are hitting.